Deciphera Pharmaceuticals, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Deciphera Pharmaceuticals, Inc. reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$194.94 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-07.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2024-02-07
- Deciphera Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2019-06-30 was -$21.46M.
- Deciphera Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2019-03-31 was -$47.38M.
- Deciphera Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2018-12-31 was -$32.30M.
- Deciphera Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2018-09-30 was -$24.43M.
- Deciphera Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$194.94M.
- Deciphera Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$178.93M.
- Deciphera Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$299.96M.
- Deciphera Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$266.49M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$194.94M 10-K · filed 2024-02-07 | |||
| 2022-12-31 | -$178.93M 10-K · filed 2024-02-07 | |||
| 2021-12-31 | -$299.96M 10-K · filed 2024-02-07 | |||
| 2020-12-31 | -$266.49M 10-K · filed 2023-02-07 | |||
| 2019-12-31 | -$192.26M 10-K · filed 2022-02-08 | |||
| 2019-06-30 | -$21.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | -$68.84M 10-Q · filed 2019-08-02 | -$101.14M derived: sum of 3 quarters · filed 2021-02-09 | -$125.58M derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-03-31 | -$47.38M 10-Q · filed 2019-05-09 | -$79.68M derived: sum of 2 quarters · filed 2021-02-09 | -$104.12M derived: sum of 3 quarters · filed 2021-02-09 | -$125.81M derived: sum of 4 quarters · filed 2021-02-09 |
| 2018-12-31 | -$32.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-09 | -$56.73M derived: sum of 2 quarters · filed 2021-02-09 | -$78.42M derived: sum of 3 quarters · filed 2021-02-09 | -$99.85M 10-K · filed 2021-02-09 |
| 2018-09-30 | -$24.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$46.13M derived: sum of 2 quarters · filed 2019-08-02 | -$67.56M 10-Q · filed 2018-11-08 | -$87.47M derived: sum of 4 quarters · filed 2020-03-09 |
| 2018-06-30 | -$21.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | -$43.12M 10-Q · filed 2019-08-02 | -$63.03M derived: sum of 3 quarters · filed 2020-03-09 | -$75.07M derived: sum of 4 quarters · filed 2020-03-09 |
| 2018-03-31 | -$21.43M 10-Q · filed 2019-05-09 | -$41.34M derived: sum of 2 quarters · filed 2020-03-09 | -$53.38M derived: sum of 3 quarters · filed 2020-03-09 | |
| 2017-12-31 | -$19.91M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | -$31.95M derived: sum of 2 quarters · filed 2020-03-09 | -$50.28M 10-K · filed 2020-03-09 | |
| 2017-09-30 | -$12.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$30.37M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | -$18.33M 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | -$25.94M 10-K · filed 2019-03-14 |